BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 35303871)

  • 21. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.
    Sterner RM; Cox MJ; Sakemura R; Kenderian SS
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31380838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review: Sustainable Clinical Development of CAR-T Cells - Switching From Viral Transduction Towards CRISPR-Cas Gene Editing.
    Wagner DL; Koehl U; Chmielewski M; Scheid C; Stripecke R
    Front Immunol; 2022; 13():865424. PubMed ID: 35784280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
    [No Abstract]   [Full Text] [Related]  

  • 27. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
    Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
    Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
    Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
    Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
    Wälchli S; Sioud M
    Methods Mol Biol; 2020; 2115():407-417. PubMed ID: 32006413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells.
    Glaser V; Flugel C; Kath J; Du W; Drosdek V; Franke C; Stein M; Pruß A; Schmueck-Henneresse M; Volk HD; Reinke P; Wagner DL
    Genome Biol; 2023 Apr; 24(1):89. PubMed ID: 37095570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A versatile system for rapid multiplex genome-edited CAR T cell generation.
    Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.
    Fix SM; Jazaeri AA; Hwu P
    Cancer Discov; 2021 Mar; 11(3):560-574. PubMed ID: 33563662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
    Ren J; Zhao Y
    Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Release Assays and Potency Assays for CAR T-Cell Interventions.
    Dias J; Cadiñanos-Garai A; Roddie C
    Adv Exp Med Biol; 2023; 1420():117-137. PubMed ID: 37258787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
    Ding R; Chao CC; Gao Q
    Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.